Bli medlem
Bli medlem

Du är här


TiGenix : TiGenix to host webcast for its 2015 half-year results on 15 September


TiGenix to host webcast for its 2015 half-year results on 15 September

Leuven (BELGIUM) - 10 September, 2015 - TiGenix NV (Euronext Brussels: TIG),
an advanced biopharmaceutical company focused on developing and
commercialising novel therapeutics from its proprietary platforms of
allogeneic expanded stem cells, will announce its half-year results for 2015
on Tuesday 15 September 2015 at 17:45 CET.

TiGenix CEO, Eduardo Bravo, and CFO, Claudia D'Augusta, will host a conference
call and webcast during which the half-year results for 2015 will be
presented, followed by a Q&A session. This event will be held on Tuesday 15
September 2015 at 18.45 CET/12.45 pm EDT.

Please dial one of the following numbers to participate:
| London, United Kingdom: +44(0)20 3427 1905 |
| New York, USA: +1646 254 3361 |
| Paris, France: +33(0)1 76 77 22 27 |
| Brussels, Belgium: +32(0)2 620 0138 |
| Madrid, Spain: +3491 114 6583 |
| Montreal, Canada: +1514 841 2154 |
| Amsterdam, Netherlands: +31(0)20 716 8256 |
| Stockholm, Sweden: +46(0)8 5033 6538 |

Confirmation Code:9894390

The webcast can be followed live online via the

The press release and the webcast slide presentation will be made available in
the Newsroom section of the TiGenix website. A replay of the webcast will be
available on the website shortly after the live webcast has finished.

For more information
Claudia D'Augusta

Chief Financial Officer

T: +34 91 804 92 64

Ana Pombo

Strategic Planning and IR Manager

T: + 34 91 804 92 64
About TiGenix

TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company
focused on developing and commercialising novel therapeutics from its
of allogeneic, or donor-derived, expanded stem cells. Two products from the
adipose-derived technology platform are currently in clinical development.
Cx601 is in Phase III for the treatment of complex perianal fistulas in
Crohn's disease patients. Cx611 has completed a Phase I/II trial in
rheumatoid arthritis, as well as
a Phase I sepsis challenge trial. Effective as of July 31, 2015, TiGenix
acquired Coretherapix, whose lead cellular product (AlloCSC-01) is currently
in a Phase II clinical trial in acute myocardial infarction (AMI).
Coretherapix is planning to initiate the clinical evaluation of AlloCSC-01 in
the chronic setting as well and is also involved in the pre-clinical
development of a pharmaceutical formulation of growth factors to treat AMI.
TiGenix also developed ChondroCelect, an autologous cell therapy product for
cartilage repair of the knee, which was the first Advanced Therapy Medicinal
Product (ATMP) to be approved by the European Medicines Agency (EMA). From
June 2014, the marketing and distribution rights of ChondroCelect were
exclusively licensed to Sobi for
the European Union (except for Finland, where it is distributed by the Finnish
Red Cross Blood Service), Norway, Russia, Switzerland and Turkey, and the
countries of the Middle East and North Africa.
TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid

For more information, please visit

Forward-looking information

This document may contain forward-looking statements and estimates with
respect to the anticipated future performance of TiGenix and the market in
which it operates. Certain of these statements, forecasts and estimates can
be recognised by the use of words such as, without limitation, "believes",
"anticipates", "expects", "intends", "plans", "seeks", "estimates", "may",
"will" and "continue" and similar expressions. They include all matters that
are not historical facts. Such statements, forecasts and estimates are based
on various assumptions and assessments of known and unknown risks,
uncertainties and other factors, which were deemed reasonable when made but
may or may not prove to be correct. Actual events are difficult to predict
and may depend upon factors that are beyond the Company's control. Therefore,
actual results, the financial condition, performance or achievements of
TiGenix, or industry results, may turn out to be materially different from
any future results, performance or achievements expressed or implied by such
statements, forecasts and estimates. Given these uncertainties, no
representations are made as to the accuracy or fairness of such
forward-looking statements, forecasts and estimates. Furthermore,
forward-looking statements, forecasts and estimates only speak as of the date
of the publication of this document. TiGenix disclaims any obligation to
update any such forward-looking statement, forecast or estimates to reflect
any change in the Company's expectations with regard thereto, or any change
in events, conditions or circumstances on which any such statement, forecast
or estimate is based, except to the extent required by Belgian law.


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: TiGenix via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.